Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $117.17 +2.36%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.13, $0.06 better than the analyst estimate of $0.07. Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.53 million.
2017 revenue guidance increased by $20 million, to $145-155 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
